Valuation: CSL Limited

Market Cap 40.46B 35.37B 32.5B 30.3B 57.46B 3,852B 58.34B 390B 152B 1,894B 152B 149B 6,525B P/E 2026 *
-45.5x
P/E 2027 * 28.2x
Enterprise Value 49.31B 43.1B 39.61B 36.92B 70.03B 4,695B 71.1B 476B 185B 2,308B 185B 181B 7,952B EV / Sales 2026 *
3.2x
EV / Sales 2027 * 3.1x
Free-Float
99.3%
Yield 2026 *
3.37%
Yield 2027 * 3.46%
1 day-0.07%
1 week+2.53%
Current month+2.12%
1 month+23.18%
3 months-15.35%
6 months-28.76%
Current year-28.87%
1 week 19.71
Extreme 19.71
20.78
1 month 16.01
Extreme 16.01
20.78
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
44.86
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Tech/Sci/R&D Officer 64 2020-09-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2013-08-13
Director/Board Member 68 2016-02-15
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+2.53% - - 40.46B
+4.73%+3.38%+19.53%-8.89% 66.56B
-1.93%+0.39%+53.64%+226.01% 56.51B
+1.07%+42.10%+42.10%+42.10% 42.98B
+3.04%+0.04%+62.66%-24.29% 31.91B
+10.01%+18.57%+161.59%-34.48% 31.65B
+2.68%+2.73%+70.72%+88.24% 23.35B
+2.87%+16.83%+1.86%+165.26% 19.46B
-0.13%+2.75%+66.32%+127.01% 17.18B
+3.58%+9.89%+75.47%+344.90% 15.12B
Average +2.58%+9.28%+61.54%+102.87% 33.86B
Weighted average by Cap. +2.41%+7.65%+56.52%+81.37%

Financials

2026 *2027 *
Net sales 15.39B 13.46B 12.37B 11.53B 21.86B 1,465B 22.19B 148B 57.71B 720B 57.77B 56.53B 2,482B 15.64B 13.67B 12.56B 11.71B 22.21B 1,489B 22.54B 151B 58.62B 732B 58.69B 57.43B 2,522B
Net income -894M -781M -718M -669M -1.27B -85.08B -1.29B -8.62B -3.35B -41.82B -3.35B -3.28B -144B 1.18B 1.03B 951M 886M 1.68B 113B 1.71B 11.41B 4.44B 55.38B 4.44B 4.35B 191B
Net Debt 8.85B 7.74B 7.11B 6.63B 12.57B 843B 12.76B 85.35B 33.18B 414B 33.22B 32.5B 1,427B 8.07B 7.05B 6.48B 6.04B 11.46B 768B 11.64B 77.84B 30.26B 378B 30.29B 29.64B 1,302B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-02 US$20.49 -0.07% 251,751
26-07-01 US$20.50 +2.19% 188,309
26-06-30 US$20.06 -0.30% 565,020
26-06-29 US$20.12 +0.70% 486,694
26-06-26 US$19.98 -2.30% 375,227
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
84.48USD
Average target price
96.61USD
Spread / Average Target
+14.36%

Quarterly revenue - Rate of surprise